12:00 AM
 | 
Jul 29, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Pennsaid 2% diclofenac regulatory update

Nuvo Research said Mallinckrodt completed a pharmacokinetic study requested by FDA in a March complete response letter for an NDA for Pennsaid 2% diclofenac sodium to treat osteoarthritis (OA) of the knee. In the letter, FDA said that 2 pharmacokinetic studies submitted by Mallinckrodt...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >